-
公开(公告)号:US20240165159A1
公开(公告)日:2024-05-23
申请号:US18494613
申请日:2023-10-25
发明人: Philip Stewart LOW , Haiyan CHU , Yong Gu LEE , Yingjuan J. LU , Christopher Paul LEAMON , Leroy W. WHEELER, II
IPC分类号: A61K35/17 , C07K14/705 , C07K16/30
CPC分类号: A61K35/17 , C07K14/70503 , C07K16/30 , C07K2317/622 , C07K2319/03 , C07K2319/033
摘要: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号:US20240075069A1
公开(公告)日:2024-03-07
申请号:US18459302
申请日:2023-08-31
申请人: ENDOCYTE, INC. , PURDUE RESEARCH FOUNDATION , SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)
发明人: Philip Stewart LOW , Haiyan CHU , Yingjuan June LU , Christopher Paul LEAMON , Leroy W. WHEELER, II , Michael C. JENSEN , James MATTHAEI
IPC分类号: A61K35/17 , A61K9/00 , A61K31/365 , A61K31/519 , A61K38/17 , A61P35/00 , C07K14/725 , C07K16/44 , C07K16/46 , C12N5/0783
CPC分类号: A61K35/17 , A61K9/0019 , A61K9/0053 , A61K31/365 , A61K31/519 , A61K38/1774 , A61P35/00 , C07K14/7051 , C07K16/44 , C07K16/46 , C12N5/0638 , C07K2317/622
摘要: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号:US11759480B2
公开(公告)日:2023-09-19
申请号:US16921400
申请日:2020-07-06
发明人: Philip Stewart Low , Haiyan Chu , Yong Gu Lee , Yingjuan J. Lu , Christopher Paul Leamon , Leroy W Wheeler, II
IPC分类号: A61K35/17 , C07K14/705 , C07K16/30
CPC分类号: A61K35/17 , C07K14/70503 , C07K16/30 , C07K2317/622 , C07K2319/03 , C07K2319/033
摘要: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号:US20230098279A1
公开(公告)日:2023-03-30
申请号:US17904442
申请日:2021-02-18
申请人: ENDOCYTE, INC.
IPC分类号: A61K51/04 , A61K39/395 , A61K38/31 , A61K31/436 , A61K31/495 , A61K31/506 , A61K31/404 , A61K31/519 , A61K31/4406
摘要: The present invention relates to combinations for use and methods of treating cancers that express prostate specific membrane antigen (PSMA). In particular, the invention provides novel therapies based on the combination of a PSMA therapeutic agent, such as radiolabeled Compound I, and immuno-oncology (I-O) therapeutic agents, wherein said I-O therapeutic agents are selected from the group consisting of LAG-3 inhibitors, TIM-3 inhibitors, GITR agonists, TGF-β inhibitors, IL15/IL-15RA complex, PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors.
-
公开(公告)号:US20220125958A1
公开(公告)日:2022-04-28
申请号:US17488810
申请日:2021-09-29
IPC分类号: A61K51/04
摘要: Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
-
公开(公告)号:US20210323985A1
公开(公告)日:2021-10-21
申请号:US17277806
申请日:2019-09-19
申请人: ENDOCYTE, INC.
IPC分类号: C07F9/38 , C07C275/16 , A61K51/04 , A61K31/662 , A61K31/17
摘要: The present disclosure relates to compounds useful as shielding agents for PSMA therapies. The present disclosure relates to methods of treating PSMA expressing cancers with one or more radiotherapeutics agents in combination with one or more shielding agents. The present disclosure relates to methods of imaging using one or more imaging agents containing a radionuclide in combination with one or more shielding agents. The present disclosure also relates to methods of making shielding agents.
-
公开(公告)号:US10857234B2
公开(公告)日:2020-12-08
申请号:US16085319
申请日:2017-03-16
申请人: Endocyte, Inc.
IPC分类号: A61K47/54 , C07K5/062 , C07K5/093 , C07K5/113 , C07K5/072 , C07K5/078 , A61K47/65 , A61K38/07 , A61P35/00
摘要: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.
-
公开(公告)号:US10647676B2
公开(公告)日:2020-05-12
申请号:US16444786
申请日:2019-06-18
申请人: Endocyte, Inc.
IPC分类号: C07D213/71 , C07D401/12 , C07D475/04 , A61K49/00 , A61K47/55 , A61K47/68
摘要: This invention pertains to bivalent linkers, and the synthesis and use thereof. In particular, this invention pertains to the synthesis and use of bivalent linkers in preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates. The present invention includes divalent linkers, which are alternatively referred to as bivalent linkers, that may be used to couple, link, bond, attach, or otherwise associate two or more chemical entities. This coupling, linking, attachment, or association may be used in the formation of conjugates of such chemical entities. Those chemical entities include targeting ligands and receptor-binding ligands, such as vitamins. Those chemical entities also include drugs for treating various diseases or disease states, and imaging and diagnostic agents for diagnosing, detecting, or otherwise monitoring various diseases or disease states.
-
公开(公告)号:US09550734B2
公开(公告)日:2017-01-24
申请号:US14746075
申请日:2015-06-22
申请人: Endocyte, Inc.
IPC分类号: C07D213/71 , A61K47/48 , A61K49/00 , C07D401/12 , C07D475/04
CPC分类号: C07D213/71 , A61K47/551 , A61K47/6803 , A61K49/0002 , C07D401/12 , C07D475/04
摘要: Bivalent linkers to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.
摘要翻译: 描述了包含在或用于制备维生素,药物,诊断剂和/或成像剂缀合物的二价连接体。
-
公开(公告)号:US08883737B2
公开(公告)日:2014-11-11
申请号:US13884842
申请日:2011-11-11
IPC分类号: A61K38/00 , A61K39/00 , A61K33/24 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/704 , A61K39/395 , A61K38/08 , A61K45/06 , A61K31/517 , A61K31/282 , A61K31/519
CPC分类号: A61K38/08 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/517 , A61K31/519 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要: Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors.
摘要翻译: 描述了用叶酸 - 长春花碱缀合物与至少一种其他化学治疗剂联合治疗上皮肿瘤的方法和组合物,其中肿瘤包括卵巢,子宫内膜或非小细胞肺癌肿瘤,包括耐铂性卵巢肿瘤和铂 - 敏感的卵巢肿瘤。
-
-
-
-
-
-
-
-
-